APA (7th ed.) Citation

Patel, M., Doi, T., Yamamoto, N., Garrido-Laguna, I., Nishioka, S., Wu, S., . . . Carneiro, B. (2025). 917O DS-3939, a tumor-associated mucin 1 (TA-MUC1)–directed antibody–drug conjugate (ADC), in patients (pts) with advanced/metastatic (adv/met) solid tumors: Initial results from a first-in-human (FIH) study. Annals of Oncology, 36, S598. https://doi.org/10.1016/j.annonc.2025.08.1486

Chicago Style (17th ed.) Citation

Patel, M.R, T. Doi, N. Yamamoto, I. Garrido-Laguna, S. Nishioka, S. Wu, C. Ostheimer, K. Nakajima, and B.A Carneiro. "917O DS-3939, a Tumor-associated Mucin 1 (TA-MUC1)–directed Antibody–drug Conjugate (ADC), in Patients (pts) with Advanced/metastatic (adv/met) Solid Tumors: Initial Results from a First-in-human (FIH) Study." Annals of Oncology 36 (2025): S598. https://doi.org/10.1016/j.annonc.2025.08.1486.

MLA (9th ed.) Citation

Patel, M.R, et al. "917O DS-3939, a Tumor-associated Mucin 1 (TA-MUC1)–directed Antibody–drug Conjugate (ADC), in Patients (pts) with Advanced/metastatic (adv/met) Solid Tumors: Initial Results from a First-in-human (FIH) Study." Annals of Oncology, vol. 36, 2025, p. S598, https://doi.org/10.1016/j.annonc.2025.08.1486.